Professor, Internal Medicine, University of Michigan Medical School
Oncology
Dr. Scott M. Schuetze, MD
|
|
Give Review
Scott Schuetze practices Oncology. He researched medicine at Oregon Health & Science University School of Medicine. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Scott Schuetze is a published physician. He has 57 publications published. The most current publication "The Ets-related transcription factor PU.1 immortalizes erythroblasts." Scott Schuetze accepts Medicare.
Publications
- SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced Sarcoma.
- Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic LipoSarcoma or LeiomyoSarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Rando...
- Gastrointestinal stromal Tumors, version 2.2014.
- A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyoSarcoma, osteo...
- Soft tissue Sarcoma, version 2.2014.
- Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant Cell tumour of bone: interim analysis of an open-label, parallel-group, phase ...
- Undifferentiated Small Round Cell Sarcoma With t(4;19)(q35;q13.1) CIC-DUX4 Fusion: A Novel Highly Aggressive Soft Tissue Tumor With Distinctive Histopathology.
- Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue Sarcomas following failure of prior chemotherapy: results of a worldwide ex...
- Cixutumumab and temsirolimus for patients with bone and soft-tissue Sarcoma: a multicentre, open-label, phase 2 trial.
- Ewing sarcoma of the kidney: case series and literature review of an often overlooked entity in the diagnosis of primary renal Tumors.
- Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing.
- Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpoint.
- DermatofibroSarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results.
- Histology-Specific Therapy for Advanced Soft Tissue Sarcoma and Benign Connective Tissue Tumors.
- Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced Sarcoma.
- Phase II Trial of Cetuximab in Patients With Metastatic or Locally Advanced Soft Tissue or Bone Sarcoma.
- Advanced or metastatic gastrointestinal stromal Tumors: Systemic treatment options.
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas.
- R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase I...
- Should patients with high-risk soft tissue Sarcoma receive adjuvant chemotherapy?
- [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteoSarcoma in children and young adults.
- Phase II study of sorafenib in patients with metastatic or recurrent Sarcomas.
- New targets for therapy of Sarcoma.
- Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue Sarcoma: clinicopathological correlation.
- Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath Tumors.
- Selection of response criteria for clinical trials of Sarcoma treatment.
- Chordoma: the nonSarcoma primary bone tumor.
- Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue Sarcomas: results of Sarcoma alliance fo...
- Chemotherapy in the management of osteoSarcoma and Ewing's Sarcoma.
- Utility of positron emission tomography in Sarcomas.
- Targeted therapy for dermatofibroSarcoma protuberans.
- [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of Tumors.
- Imaging and response in soft tissue Sarcomas.
- So-called "inflammatory leiomyoSarcoma'': a series of 3 cases providing additional insights into a rare entity.
- Adjuvant therapy for soft tissue Sarcoma.
- Use of positron emission tomography in localized extremity soft tissue Sarcoma treated with neoadjuvant chemotherapy.
- Deep-seated, well differentiated lipomatous Tumors of the chest wall and extremities: the role of cytogenetics in classification and prognostication.
- Fluorodeoxyglucose positron emission tomography scanning: basic principles and imaging of adult soft-tissue Sarcomas.
- Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibroSarcoma protuberans.
- The epidemiology of malignant giant Cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004).
- Imatinib mesylate in advanced dermatofibroSarcoma protuberans: pooled analysis of two phase II clinical trials.
- Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with Sarcoma and Ewing''s Sarcoma: a phase 1 expans...
- Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.
- Large cell non-Hodgkin's lymphoma and Hodgkin's disease arising synchronously in a patient with chronic lymphocytic Leukemia: importance of immunocytochemistry.
- Acquired protein S deficiency with multiple thrombotic complications after orthotopic Liver transplant.
- The Sfpi-1 proviral integration site of Friend erythroLeukemia encodes the ets-related transcription factor Pu.1.
- Role of the PU.1 transcription factor in controlling differentiation of Friend erythroLeukemia cells.
- Complications of a temozolomide overdose: a case report.
- AngioSarcoma metastatic to the orbit.
- The Ets-related transcription factor PU.1 immortalizes erythroblasts.
- A common site for immortalizing proviral integrations in Friend erythroLeukemia: molecular cloning and characterization.
- Efficacy and safety of trabectedin in patients with advanced or metastatic lipoSarcoma or leiomyoSarcoma after failure of prior anthracyclines and ifosfamide: results ...
- NCCN Task Force report: update on the management of patients with gastrointestinal stromal Tumors.
- Influence of age upon Ifosfamide-induced nephrotoxicity.
- FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade Sarcoma.
- Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal Tumors.
Schools
Oregon Health Sciences University
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Benesys
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Care Network PCP Focus Network
- Group Employees PPO
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- Health Alliance
- Choice Care PPO
- Medicaid
- Medical Mutual of Ohio
- Medicare MCR
- Meritain Health
- Molina
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- NGS CoreSource
- Paramount
- PHP-Physicians Health Plan
- Priority PPO
- Tricare
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Washington -
Duke University Hospital -
Oregon Health & Science University School of Medicine
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1548346414 | |
| NPPES Provider LastName | SCHUETZE | |
| NPPES Provider FirstName | SCOTT | |
| NPPES Provider ZIPCode | 481095912 | |
| NPPES Provider State | MI | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 358.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1548346414 |
| Last Name Of The Provider | SCHUETZE |
| First Name Of The Provider | SCOTT |
| View All |
Similar Doctors
|
|
Dr. Max S. Wicha, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jeffrey B. Smerage, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Norah L. Henry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kunal C. Kadakia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sheetal M. Kircher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maha H. Hussain, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. William D. Ensminger, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Assuntina G. Sacco, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anne F. Schott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Muneesh Tewari, MD
This Doctor is OpenDoctor Recommended.
|